The study progression of recombinant apolipoprotein A-IMilano in cardiovascular protection and therapy of coronary heart disease
Zhu, W.-x.; Chen, B.-s.
Zhonghua Xin Xue Guan Bing Za Zhi 33(7): 673-675
2005
ISSN/ISBN: 0253-3758 PMID: 16080828 Document Number: 589815
Document emailed within 1 workday
Related Documents
Einecke, D. 2014: SIGNIFY study is a disappointment. Ivabradine cannot stop of the progression of coronary heart disease MMW Fortschritte der Medizin 156(15): 1Arntz, H.R.; Wunderlich, W.; Schnitzer, L.; Stern, R.; Fischer, F.; Agrawal, R.; Linderer, T.; Schultheiss, H.P. 1999: Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study Zeitschrift für Kardiologie 88(8): 582-590
Sidorenko, B.A.; Lupanov, V.P.; Savchenko, A.P.; Mazaev, V.P.; Borisova, G.A. 1985: Progression of coronary arteriosclerosis based on the data from repeat coronary angiography and the clinical course of ischemic heart disease Terapevticheskii Arkhiv 57(9): 9-14
Yuan, S.; Ma, Y-tong.; Xie, X.; Yang, Y-ning.; Fu, Z-yan.; Ma, X.; Li, X-mei.; Liu, F.; Chen, B-dang. 2011: Association between apolipoprotein A5 gene polymorphism and coronary heart disease in the Han population from Xinjiang Zhonghua Liu Xing Bing Xue Za Zhi 32(1): 51-54
Jackson, S.A.; Burke, G.L.; Thach, C.; Cushman, M.; Ives, D.; Powe, N.; Manolio, T.A. 2001: Incidence and predictors of coronary heart disease among older African Americans--the Cardiovascular Health Study Journal of the National Medical Association 93(11): 423-429
Pan, J.P.; Chiang, A.N.; Tai, J.J.; Wang, S.P.; Chang, M.S. 1995: Restriction fragment length polymorphisms of apolipoprotein B gene in Chinese population with coronary heart disease Clinical Chemistry 41(3): 424-429
Zhu, T.; Wang, Z.; Zhao, S. 1998: Effect of apolipoprotein e gene plasma levels of lipids, lipoproteins, apolipoproteins and its relation with coronary heart disease Hunan Yi Ke da Xue Xue Bao 23(2): 149-151
Follath, F. 1999: New cardiovascular drugs: expanded therapeutic possibilities in coronary heart disease and in heart failure Praxis 88(18): 809-813
Eckert, S.; Tschöpe, D. 2005: Cardiovascular protection in diabetic patients with heart disease in the doctor's office MMW Fortschritte der Medizin 147(43): 43-46
Weber, M.; McNicoll, S.; Marcil, M.; Connelly, P.; Lussier-Cacan, S.; Davignon, J.; Latour, Y.; Genest, J. 1997: Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians Canadian Journal of Cardiology 13(3): 253-260
Lakka, H.M.; Lakka, T.A.; Tuomilehto, J.; Sivenius, J.; Salonen, J.T. 2000: Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study Archives of Internal Medicine 160(8): 1160-1168
Milanović, S.M.ć; Uhernik, A.I.ć; Dzakula, A.; Brborović, O.; Poljicanin, T.; Fister, K.; Juresa, V.; Heim, I.; Vrazić, H.; Bergovec, M.; Kern, J.; Vuletić, S. 2012: The CroHort study: cardiovascular behavioral risk factors in adults, school children and adolescents, hospitalized coronary heart disease patients, and cardio rehabilitation groups in Croatia Collegium Antropologicum 36(Suppl 1): 265-268
Lowe, G.; Rumley, A.; Norrie, J.; Ford, I.; Shepherd, J.; Cobbe, S.; Macfarlane, P.; Packard, C. 2000: Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study Thrombosis and Haemostasis 84(4): 553-558
Nogués, X.; Sentí, M.; Pedro-Botet, J.; Molina, L.; Serrat, R.; Pons, S.; Rubiés-Prat, J. 1992: Coronary heart disease and lipoprotein (a): relationship with other lipid cardiovascular risk factors Medicina Clinica 98(5): 171-174
Patel, P.; Mendall, M.A.; Carrington, D.; Strachan, D.P.; Leatham, E.; Molineaux, N.; Levy, J.; Blakeston, C.; Seymour, C.A.; Camm, A.J. 1995: Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors BMJ 311(7007): 711-714
Jenni, D.; Osterwalder, R.; Osswald, S.; Buser, P.; Pfisterer, M. 2001: Are we treating coronary heart disease and heart failure appropriately in the clinic and ambulatory care? Secondary prevention and drug therapy 1998 Praxis 90(41): 1759-1765
Kou, W.R.; Gao, R.L.; Chen, Z.J. 1987: A correlative study of thallium-201 myocardial imaging, electrocardiography and coronary arteriography in 50 patients with coronary heart disease Zhonghua Xin Xue Guan Bing Za Zhi 15(2): 89-91 127
Li, X.; Song, J.P.; Wang, K.P. 1992: A comparative study of coronary arteriography and myocardial emission computed tomography in the diagnosis of coronary heart disease Zhonghua Nei Ke Za Zhi 31(10): 611
García-Palmieri, M.R.; Feliberti, M.; Costas, Rúl.; Colón, A.A.; Cruz-Vidal, M.; Cortés-Alicea, M.; Ayala, A.M.; Sobrino, R.; Torres, R.; García-Palmieri, M.R.; Feliberti, M.; Costas, Rúl. 2002: An epidemiological study on coronary heart disease in PR. The Puerto Rico Heart Health Program. 1969 Boletin de la Asociacion Medica de Puerto Rico 94(1-12): 61-67
Long Term Intervention With Pravastatin, I.Ischaemic Disease Study Group 1998: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels New England Journal of Medicine 339(19): 1349-1357